Candice Brannen
About Candice Brannen
Candice Brannen serves as the Senior Director of Cell and Gene Therapy Development at Precision BioSciences, Inc., where she applies her expertise in product development within the IVD and medical device industry. She holds a PhD in Physical and Materials Chemistry from North Carolina State University and has extensive experience in genomics and rare diseases.
Current Role at Precision BioSciences
Candice Brannen serves as the Program Leader and Senior Director of Cell and Gene Therapy Development at Precision BioSciences, Inc. since 2020. In this role, she focuses on advancing the company's proprietary ARCUS® genome editing platform. This platform aims to tackle challenges in oncology, genetic diseases, and agricultural applications. Her leadership contributes to the strategic direction and execution of projects within the cell and gene therapy sector.
Education and Expertise
Candice Brannen earned her Doctor of Philosophy (PhD) in Physical and Materials Chemistry from North Carolina State University, where she studied from 2001 to 2006. Prior to that, she completed her Bachelor of Science (BS) in Chemistry at The University of Georgia from 1995 to 2000. Her educational background provides a strong foundation for her expertise in product development and launch within the IVD and medical device industries, particularly in genomics and cell and gene therapy.
Professional Background
Candice Brannen has held various positions in the biotechnology and medical device sectors. She worked as the Business Unit Head for Rare Disease Newborn Screening at Baebies from 2016 to 2020. Prior to that, she served as Program Leader and Staff Scientist at Lord Corporation from 2007 to 2011. Her experience also includes roles at Advanced Liquid Logic and Illumina, where she focused on rare diseases and oncology, respectively. Additionally, she was a Post Doctoral Associate at the University of North Carolina at Chapel Hill.
Achievements in Product Development
Throughout her career, Candice Brannen has demonstrated strong skills in product conception, development, and launch. She has specifically contributed to the development of products in the genomics and cell and gene therapy sectors, targeting oncology and rare diseases. Her roles have involved overseeing significant projects that align with her expertise in the medical device industry.